自进入临床以来，Ra-223积累了丰富的循证证据。整体而言，其临床应用是逐渐由后线治疗向早期治疗迈进，并在联合治疗策略中展现出令人振奋的疗效潜力。本次ESMO公布的RAPSON研究结果为早期启动Ra-223提供了新的证据，更重要的是为患者提供了更佳的 ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.

Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

Nilsson and colleagues conducted a small, randomized, placebo-controlled, phase II trial of the alpha-emitter radium-223 (223 Ra) for the treatment of these patients. A phase I trial in patients ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

2024年欧洲肿瘤内科学会年会（2024 ESMO）将于当地时间2024年9月13日至17日在西班牙巴塞罗那正式召开。一直以来，最新突破性摘要（LBA，Late Breaking Abstracts）都是年会中备受瞩目的焦点。同时，鉴于前列腺癌是我国泌尿男生殖系统最常见的恶性肿瘤，本次ESMO大会公布的前列腺癌重磅进展对于我国前列腺癌诊疗实践具有重要参考价值。

Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Radium-223 improves OS and delays the time to the first symptomatic skeletal event in bone metastatic patients who are unfit for or pretreated with docetaxel. The identification of new drug ...

This image depicts a binding molecule delivering radium-223 to a cancer cell. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert!

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...